A literature review from 2021 found that as many as 12% of people with an EGFR mutation have a type called the exon 20 insertion mutation. If you have EGFR-positive lung cancer, it means your EGFR ...

The most common EGFR mutations in people with lung cancer are the EGFR exon 19 deletion mutation and EGFR exon 21 L858R point mutation. They respond to targeted therapies called EGFR inhibitors.

The open-label RAMOSE trial involved patients and investigators at 11 sites in the U.S. Eligible patients had newly diagnosed advanced/metastatic NSCLC and EGFR exon 19 deletion or L858R mutations.

The CHMP has recommended Rybrevant (amivantamab) for use alongside carboplatin and pemetrexed chemotherapy as a first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR exon ...

The US regulator has cleared Tagrisso (osimertinib) for patients with stage 3 non-small cell lung cancer (NSCLC) expressing EGFR exon 19 or exon 21 (L858R) mutations that cannot be treated with ...

The target enrollment for a global Phase 3 study of firmonertinib in first-line NSCLC patients with EGFR exon 20 insertion mutations has been achieved, and interim data shows encouraging results ...

First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC ...

DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase inhibitor of the EGFR, which binds irreversibly to certain mutant forms of ...

The committee has also recommended an extension of authorization for the product as a monotherapy for the treatment of adult patients with advanced NSCLC with activating EGFR exon 20 insertion ...

Initiated a cohort to evaluate ORIC-114 monotherapy for the 1L treatment of patients with NSCLC harboring EGFR exon 20 insertion mutations. Announced the completion of the dose escalation portion ...